| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 919.96 | 7.2% | 129.0% |
| Total Income | 935.88 | 7.3% | 132.0% |
| Expenditure | 810.64 | 6.9% | 109.6% |
| PBT | 125.24 | 71.4% | 667.9% |
| Net Profit | 66.38 | 36.8% | 539.5% |
| OPM | 20.03% | 4.38pp | 8.60pp |
| NPM | 7.09% | 1.53pp | 4.52pp |
| EPS | 1.20 | 34.8% | 224.3% |
Viyash Scientific: FY26 PAT up 1324% to ₹2,246 Million
19 May 2026 · 19 May, 7:23 pm
Summary
Viyash Scientific Limited announced strong financial results for the fourth quarter and full fiscal year ended March 31, 2026. Revenues for Q4 FY26 increased by 19.1% to ₹ 9,200 Million, while full-year FY26 revenues grew 13.8% to ₹ 34,203 Million. The company achieved a significant turnaround, with Q4 FY26 EBITDA surging by 63.9% to ₹ 2,001 Million and full-year EBITDA rising 59.6% to ₹ 7,025 Million, pushing the FY26 EBITDA margin to 20.5%. Profit After Tax for FY26 saw a remarkable 1334.0% jump to ₹ 2,246 Million, reflecting the benefits of integration and operational efficiencies. Managing Director and Group CEO, Dr. Hari Babu Bodepudi, highlighted FY26 as a transformative year, attributing the strong performance to successful integration, improved operating leverage, and meaningful merger synergies, while expressing excitement for the product pipeline and future growth avenues.
Key Highlights
- 1
Viyash Scientific Limited reported Q4 FY26 revenues of ₹ 9,200 Million, marking a 19.1% increase year-over-year.
- 2
EBITDA for Q4 FY26 reached ₹ 2,001 Million, surging by 63.9%, making it the strongest quarter in the Company's history.
- 3
For the full fiscal year 2026, revenues grew by 13.8% to ₹ 34,203 Million compared to the previous year.
- 4
FY26 EBITDA saw a robust increase of 59.6% to ₹ 7,025 Million, with the EBITDA margin improving significantly to 20.5% from 14.6% in FY25.
- 5
Profit After Tax (PAT) for FY26 dramatically rose by 1334.0% to ₹ 2,246 Million.
- 6
The company reported a healthy Net Debt / EBITDA ratio of 0.2x, indicating a significantly deleveraged balance sheet.
- 7
Fiscal Year 2026 was a transformative year for Viyash Scientific, marked by successful integration and meaningful merger synergies.
Management Comments
Dr Hari Babu Bodepudi
Fiscal Year 2026 has been a transformative year for Viyash Scientific, marked by the successful integration of our facilities, operations, and corporate functions into one unified platform. Q4 was the strongest quarter in the Company’s history, with merger synergies beginning to reflect meaningfully in our financial performance. The integrated platform has strengthened execution, improved operating leverage, and enhanced our resilience amidst ongoing geopolitical and maritime disruptions. We continue to navigate these challenges through disciplined asset utilization, cost controls, and agile pricing strategies. As we enter FY27, we are excited about our product pipeline and growth roadmap. With a significantly deleveraged balance sheet, we are also actively evaluating selective inorganic opportunities to further strengthen our platform and create long-term value
Informational and educational content only. Not investment advice.